Thermo Fisher Scientific Inc. (NYSE:TMO) Stock Holdings Increased by Wells Trecaso Financial Group LLC

Wells Trecaso Financial Group LLC boosted its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.3% in the first quarter, Holdings Channel reports. The institutional investor owned 10,938 shares of the medical research company’s stock after acquiring an additional 145 shares during the quarter. Thermo Fisher Scientific makes up approximately 1.8% of Wells Trecaso Financial Group LLC’s holdings, making the stock its 21st largest position. Wells Trecaso Financial Group LLC’s holdings in Thermo Fisher Scientific were worth $5,443,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the stock. Cypress Advisory Group LLC purchased a new stake in shares of Thermo Fisher Scientific during the 4th quarter worth about $253,000. Intact Investment Management Inc. raised its position in Thermo Fisher Scientific by 34.0% during the fourth quarter. Intact Investment Management Inc. now owns 2,600 shares of the medical research company’s stock valued at $1,353,000 after acquiring an additional 660 shares in the last quarter. Purkiss Capital Advisors LLC bought a new stake in Thermo Fisher Scientific in the fourth quarter worth approximately $1,121,000. LaFleur & Godfrey LLC increased its stake in shares of Thermo Fisher Scientific by 9.1% during the 4th quarter. LaFleur & Godfrey LLC now owns 29,767 shares of the medical research company’s stock worth $15,486,000 after purchasing an additional 2,488 shares during the last quarter. Finally, Deutsche Bank AG lifted its stake in shares of Thermo Fisher Scientific by 9.5% in the 4th quarter. Deutsche Bank AG now owns 1,321,633 shares of the medical research company’s stock valued at $687,553,000 after purchasing an additional 114,277 shares during the last quarter. 89.23% of the stock is owned by institutional investors and hedge funds.

Thermo Fisher Scientific Trading Down 3.7%

Shares of TMO opened at $390.17 on Wednesday. The stock’s 50-day moving average price is $415.31 and its 200 day moving average price is $490.41. The company has a quick ratio of 1.38, a current ratio of 1.77 and a debt-to-equity ratio of 0.64. Thermo Fisher Scientific Inc. has a 12-month low of $389.86 and a 12-month high of $627.88. The firm has a market capitalization of $147.29 billion, a price-to-earnings ratio of 22.88, a P/E/G ratio of 2.14 and a beta of 0.78.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Wednesday, April 23rd. The medical research company reported $5.15 EPS for the quarter, beating analysts’ consensus estimates of $5.10 by $0.05. Thermo Fisher Scientific had a return on equity of 17.15% and a net margin of 15.19%. The business had revenue of $10.36 billion during the quarter, compared to analyst estimates of $10.23 billion. During the same period in the prior year, the company posted $5.11 earnings per share. Thermo Fisher Scientific’s revenue was up .2% on a year-over-year basis. As a group, research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, July 15th. Stockholders of record on Friday, June 13th will be given a dividend of $0.43 per share. The ex-dividend date is Friday, June 13th. This represents a $1.72 annualized dividend and a dividend yield of 0.44%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.09%.

Insider Buying and Selling

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of the company’s stock in a transaction on Monday, April 28th. The stock was sold at an average price of $429.93, for a total value of $128,979.00. Following the sale, the executive vice president now directly owns 23,167 shares in the company, valued at $9,960,188.31. This represents a 1.28% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Company insiders own 0.33% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have weighed in on TMO. UBS Group cut their target price on Thermo Fisher Scientific from $715.00 to $500.00 and set a “buy” rating on the stock in a report on Thursday, April 24th. Evercore ISI reduced their target price on Thermo Fisher Scientific from $585.00 to $500.00 and set an “outperform” rating for the company in a report on Thursday, April 24th. Wall Street Zen upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a report on Wednesday, May 21st. Scotiabank reduced their price objective on shares of Thermo Fisher Scientific from $650.00 to $605.00 and set a “sector perform” rating for the company in a research note on Friday, April 25th. Finally, Citigroup dropped their target price on shares of Thermo Fisher Scientific from $650.00 to $570.00 and set a “neutral” rating on the stock in a report on Tuesday, March 4th. Four research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to MarketBeat, Thermo Fisher Scientific presently has an average rating of “Moderate Buy” and an average target price of $605.30.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.